tradingkey.logo

Biote Corp

BTMD
2.230USD
+0.110+5.19%
Close 02/06, 16:00ETQuotes delayed by 15 min
68.42MMarket Cap
2.46P/E TTM

Biote Corp

2.230
+0.110+5.19%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Biote Corp

Currency: USD Updated: 2026-02-06

Key Insights

Biote Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 83 out of 156 in the Professional & Commercial Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.84.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Biote Corp's Score

Industry at a Glance

Industry Ranking
83 / 156
Overall Ranking
231 / 4521
Industry
Professional & Commercial Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Biote Corp Highlights

StrengthsRisks
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.54% year-on-year.
Undervalued
The company’s latest PE is 2.46, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 20.37M shares, decreasing 0.13% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 2.54K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.51.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
4.843
Target Price
+128.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Biote Corp is 7.11, ranking 93 out of 156 in the Professional & Commercial Services industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 47.96M, representing a year-over-year decrease of 6.67%, while its net profit experienced a year-over-year decrease of 23.49%.

Score

Industry at a Glance

Previous score
7.11
Change
0

Financials

7.55

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.56

Operational Efficiency

8.44

Growth Potential

4.90

Shareholder Returns

7.12

Biote Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Biote Corp is 5.92, ranking 117 out of 156 in the Professional & Commercial Services industry. Its current P/E ratio is 2.46, which is 8296.41% below the recent high of 206.76 and 2011.73% above the recent low of -47.08.

Score

Industry at a Glance

Previous score
5.92
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 83/156
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Biote Corp is 8.00, ranking 31 out of 156 in the Professional & Commercial Services industry. The average price target is 5.03, with a high of 8.00 and a low of 3.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
4.843
Target Price
+128.46%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

16
Total
9
Median
12
Average
Company name
Ratings
Analysts
Biote Corp
BTMD
5
S&P Global Inc
SPGI
28
Equifax Inc
EFX
25
Moody's Corp
MCO
25
TransUnion
TRU
21
Factset Research Systems Inc
FDS
19
1
2
3

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Biote Corp is 6.45, ranking 121 out of 156 in the Professional & Commercial Services industry. Currently, the stock price is trading between the resistance level at 2.59 and the support level at 1.95, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.18
Change
0.27

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(4)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.022
Neutral
RSI(14)
45.717
Neutral
STOCH(KDJ)(9,3,3)
47.728
Neutral
ATR(14)
0.141
Low Volatility
CCI(14)
33.352
Neutral
Williams %R
41.176
Buy
TRIX(12,20)
-0.749
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
2.196
Buy
MA10
2.157
Buy
MA20
2.261
Sell
MA50
2.483
Sell
MA100
2.672
Sell
MA200
3.194
Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Biote Corp is 7.00, ranking 76 out of 156 in the Professional & Commercial Services industry. The latest institutional shareholding proportion is 73.91%, representing a quarter-over-quarter increase of 2.95%. The largest institutional shareholder is The Vanguard, holding a total of 1.44M shares, representing 4.48% of shares outstanding, with 4.86% increase in holdings.

Score

Industry at a Glance

Previous score
7.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Roystone Capital Management LP
4.62M
--
325 Capital LLC
4.55M
--
Heyer (Andrew R)
2.48M
-1.43%
Bandera Partners LLC
2.28M
--
BlackRock Institutional Trust Company, N.A.
1.59M
-0.99%
The Vanguard Group, Inc.
Star Investors
1.43M
+0.24%
Heyer (Steven J)
1.06M
--
Acadian Asset Management LLC
694.61K
+1.38%
Geode Capital Management, L.L.C.
612.24K
-0.72%
Dimensional Fund Advisors, L.P.
567.25K
-8.15%
1
2

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Professional & Commercial Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Biote Corp is 3.57, ranking 114 out of 156 in the Professional & Commercial Services industry. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
3.57
Change
0
Beta vs S&P 500 index
1.14
VaR
--
240-Day Maximum Drawdown
+55.39%
240-Day Volatility
+70.03%

Return

Best Daily Return
60 days
+9.17%
120 days
+9.17%
5 years
--
Worst Daily Return
60 days
-9.23%
120 days
-9.23%
5 years
--
Sharpe Ratio
60 days
-1.78
120 days
-1.24
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+55.39%
3 years
+75.24%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.94
3 years
-0.23
5 years
--
Skewness
240 days
-0.67
3 years
-0.28
5 years
--

Volatility

Realised Volatility
240 days
+70.03%
5 years
--
Standardised True Range
240 days
+9.05%
5 years
--
Downside Risk-Adjusted Return
120 days
-210.11%
240 days
-210.11%
Maximum Daily Upside Volatility
60 days
+49.33%
Maximum Daily Downside Volatility
60 days
+38.50%

Liquidity

Average Turnover Rate
60 days
+0.49%
120 days
+0.60%
5 years
--
Turnover Deviation
20 days
+50.95%
60 days
+1.81%
120 days
+22.71%

Peer Comparison

Professional & Commercial Services
Biote Corp
Biote Corp
BTMD
6.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Brady Corp
Brady Corp
BRC
8.77 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
McGrath RentCorp
McGrath RentCorp
MGRC
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ennis Inc
Ennis Inc
EBF
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
RB Global Inc
RB Global Inc
RBA
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Brinks Co
Brinks Co
BCO
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI